Anticoagulant reversal (warfarin, DOAC, heparin)MANAGEMENT

HEMATOLOGIC AND ONCOLOGIC PRESENTATIONS · 12 SECTIONS

⚲

514 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Acute chest syndrome Acute Hemolytic Transfusion Reaction Anticoagulant reversal (warfarin, DOAC, heparin)Aplastic Anemia (Crisis)Autoimmune Hemolytic Anemia CAR-T and cytokine release syndrome Coagulopathy Delayed Hemolytic Transfusion Reaction Disseminated Intravascular Coagulation (DIC)Essential Thrombocythemia Febrile Non-hemolytic Transfusion Reaction Graft Versus Host Disease (Acute)Hemolytic Uremic Syndrome (HUS)Hemophilia A (Bleeding Crisis)Heparin-Induced Thrombocytopenia (HIT)Hyperviscosity syndrome Immune checkpoint inhibitor toxicity Immune Thrombocytopenic Purpura (ITP)Leukemoid Reaction Leukostasis Massive transfusion protocol Myelofibrosis Neutropenic enterocolitis (typhlitis)Paroxysmal Nocturnal Hemoglobinuria Polycythemia Vera (Crisis)Pure Red Cell Aplasia Sickle Cell (Acute Chest Syndrome)Sickle Cell (Splenic Sequestration)Sickle cell crisis (vaso-occlusive)Symptomatic anemia Thrombocytopenia (severe)Thrombotic Thrombocytopenic Purpura (TTP)Transfusion-Associated Circulatory Overload (TACO)Transfusion-Related Acute Lung Injury (TRALI)Tumor lysis syndrome Von Willebrand Disease (Bleeding)

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp43

Immediate priorities

›Initial stabilization

›Airway protection triggers

›Declining mental status from suspected intracranial hemorrhage

›Massive hematemesis or hemoptysis with aspiration risk

›Breathing and oxygenation

›SpO2 94-98%

›Avoid hyperoxia once target reached

›Circulation and access

›Two large-bore peripheral IV lines

›Ultrasound-guided access preferred over blind central line in coagulopathy

›Avoid subclavian site given noncompressible bleeding risk

›Point of care glucose

›Hypoglycemia correction as cause of altered mental status

›Baseline neurologic assessment

›Glasgow Coma Scale documented before sedation

›Serial exams to detect hematoma expansion

Major bleeding triage

›ISTH major bleeding criteria gate the reversal pathway

›Fatal bleeding

›Symptomatic bleeding in a critical site

›Intracranial

›Intraspinal

›Intraocular

›Retroperitoneal

›Intra-articular

›Pericardial

›Intramuscular with compartment syndrome

02History/hx46

Anticoagulant exposure characterization

›Agent identification

›Warfarin

›Indication and target INR range

›Direct oral anticoagulant

›Dabigatran

›Apixaban

›Rivaroxaban

›Edoxaban

›Heparin class

›Unfractionated heparin

›Low molecular weight heparin

›Dosing and timing

›Last dose amount

›Time of last dose

›Recent dose changes or missed doses

›Supratherapeutic self-administration or intentional overdose

Bleeding history and risk factors

›Current bleeding event

›Bleeding site and duration

›Estimated blood loss

›Trauma or spontaneous onset

›Prior bleeding history

›Prior major bleeding on anticoagulation

›Peptic ulcer disease or known GI lesion

›Prior intracranial hemorrhage

›Bleeding risk modifiers

›Concurrent antiplatelet therapy

03Physical Exam/exam25

Bleeding source localization

›Systematic source survey

›Neurologic exam

›Focal deficit

›Pupillary asymmetry

›Abdominal exam

›Distension or peritonism

›Flank ecchymosis

›Rectal and gastrointestinal exam

›Melena or hematochezia

›Musculoskeletal exam

›Tense swollen limb

›Distal neurovascular status for compartment concern

›Skin and mucosal exam

›Ecchymosis pattern

›Oozing from puncture sites suggesting coagulopathy

Hemodynamic and neurologic findings

›Perfusion assessment

›Heart rate and blood pressure trend

›Capillary refill

›Orthostatic changes if stable enough to test

›Neurologic trend

›Serial Glasgow Coma Scale

›New or worsening headache

›Hematoma expansion concern

›Cushing reflex

›Bradycardia and hypertension with irregular respirations

04Differential Diagnosis/ddx34

Life-threatening bleeding by site

›Intracranial hemorrhage

›Nontraumatic intracerebral hemorrhage ICD-10 I61.9

›Highest mortality bleeding site

›Gastrointestinal hemorrhage

›Gastrointestinal hemorrhage unspecified ICD-10 K92.2

›Most common major bleeding site overall

›Retroperitoneal hemorrhage

›Flank pain and unexplained hypotension

›Often occult until decompensation

›Hemothorax

›Hemothorax ICD-10 J94.2

›Diminished breath sounds and dullness to percussion

›Cardiac tamponade from hemopericardium

›Cardiac tamponade ICD-10 I31.4

›Beck triad

›Intramuscular hemorrhage with compartment syndrome

›Tense painful limb with distal ischemia

›Fasciotomy consideration

Coagulopathy causes to distinguish from anticoagulant effect

›Alternative coagulopathy drivers

›Disseminated intravascular coagulation

›Sepsis or malignancy context

›Acute liver failure

›Global factor deficiency including factor V

›Vitamin K deficiency unrelated to warfarin

›Malnutrition or malabsorption

›Acquired factor inhibitor

05Laboratory Tests/lt40

Coagulation assay interpretation by agent

›Warfarin monitoring

›INR and prothrombin time

›Reflects factors II, VII, IX, X depletion

›Guides prothrombin complex concentrate dosing tier

›Unfractionated heparin monitoring

›Activated partial thromboplastin time

›Reflects intrinsic and common pathway inhibition

›Dabigatran assessment

›Thrombin time

›Highly sensitive, normal result reasonably excludes clinically relevant dabigatran effect

›Dilute thrombin time or ecarin clotting time

›Quantitative level where available

›Activated partial thromboplastin time limitation

›Prolonged but non-linear at high concentration

›Factor Xa inhibitor assessment

›Drug-calibrated anti-Xa assay

›Most reliable quantitative measure for apixaban and rivaroxaban

›Standard heparin-calibrated anti-Xa assay limitation

›May not accurately reflect DOAC concentration

Baseline hematology and organ function

›Initial panel

›Complete blood count

›Baseline hemoglobin and platelet count

›Serial hemoglobin trend during active bleeding

›Basic metabolic panel

›Creatinine for dabigatran clearance and renal dosing decisions

›Liver function tests

06Diagnostic Tests/dt36

Scoring Systems

›Bleeding and thrombotic risk frameworks

›HAS-BLED score

›Hypertension, abnormal renal or liver function, stroke history, bleeding history, labile INR, elderly age over 65, drug or alcohol use

›Maximum score 9

›Score of 3 or more associated with high bleeding risk warranting caution

›CHA2DS2-VASc score

›Used to weigh thromboembolic risk against bleeding risk in resumption decisions

›ISTH major bleeding definition

›Formal classification underlying the triage gate in the Approach section

MRI

›Limited acute role

›Time sensitivity in unstable bleeding

›Not first line while hemodynamically unstable

›Delayed use cases

›Equivocal small intracranial hemorrhage

›Underlying vascular lesion evaluation once stable

›Contraindication considerations

›Unstable patient with monitoring limitations

›Non-MRI-conditional devices

›Core imaging

›CT head noncontrast

›First test for suspected intracranial hemorrhage

›CT angiography spot sign

›Marker of active extravasation and hematoma expansion risk

›CT abdomen and pelvis with contrast

›Retroperitoneal or intra-abdominal source when stable enough to transport

07Disposition/dispo29

Level of care determination

›ICU admission criteria

›Any major bleeding criterion met

›Intracranial hemorrhage regardless of size

›Hemodynamic instability

›Reversal agent administration

›Post-reversal monitoring requirement

›Monitored bed criteria

›Non-major bleeding with stable vitals

›Serial hemoglobin and coagulation checks

Transfer criteria

›Non-tertiary center triggers

›No neurosurgical coverage for intracranial hemorrhage

›No interventional radiology or endoscopy for source control

›Reversal agent unavailable locally

›Andexanet alfa or idarucizumab stock limitation

›Transfer coordination

›Reversal initiated before transfer whenever possible

Resumption of anticoagulation and discharge readiness

›Resumption timing framework

›Risk-benefit weighing

›Thromboembolic risk against rebleeding risk individualized per patient

›Intracranial hemorrhage

›Resumption commonly deferred 4 to 8 weeks based on observational data and repeat imaging stability

›Gastrointestinal hemorrhage

›Resumption commonly considered within 24 to 72 hours once hemostasis achieved and hemodynamically stable

›Mechanical heart valve

›Early bridging with therapeutic unfractionated heparin or low molecular weight heparin once procedural hemostasis achieved given high thrombotic risk of prolonged interruption

08Treatment/t166

Major bleeding gate and general hemostatic measures

›Local and mechanical hemostasis

›Direct pressure or packing for compressible sites

›Endoscopic or angiographic source control for internal bleeding

›Escalate to definitive reversal only when major bleeding criteria are met or urgent procedure is required

Warfarin reversal

›4-factor prothrombin complex concentrate

›INR-based dosing

›INR 2 to less than 4, 25 units/kg IV, maximum 2500 units

›INR 4 to 6, 35 units/kg IV, maximum 3500 units

›INR greater than 6, 50 units/kg IV, maximum 5000 units

›Dosing weight cap

›Actual body weight used up to a cap of 100 kg, patients heavier than 100 kg dosed as if 100 kg

›Administration

›Single IV infusion, rate per product labeling

›Recheck INR approximately 30 minutes after infusion

›Vitamin K

›IV dosing

›10 mg IV diluted, infused slowly over 30 minutes to reduce anaphylactoid reaction risk

›Repeat every 12 hours if INR remains elevated

›Why oral and subcutaneous routes are inadequate for major bleeding

›Oral vitamin K requires 24 to 48 hours for meaningful INR correction

›Subcutaneous absorption is erratic and unpredictable in this setting

›Intramuscular route is relatively contraindicated given injection site hematoma risk in coagulopathy

›Rationale for co-administration with prothrombin complex concentrate

›Replaced factors have short half-life, factor VII approximately 6 hours

›Vitamin K sustains reversal and prevents early INR rebound

›Fresh frozen plasma when prothrombin complex concentrate unavailable

›Dosing

›10 to 15 mL/kg IV

›Why it is inferior to prothrombin complex concentrate

›Requires thawing delay before administration

›Larger infused volume increases transfusion-associated circulatory overload risk

›Slower and less complete INR correction, especially at high baseline INR

›Carries transfusion reaction and infectious exposure risk absent from factor concentrates

Dabigatran reversal

›Idarucizumab

›Dosing

›5 g IV total, given as two sequential 2.5 g/50 mL doses no more than 15 minutes apart

›Repeat 5 g dose if bleeding continues or before urgent surgery with persistently elevated clotting times

›Onset

›Reverses anticoagulant effect within minutes

›Activated charcoal for very recent ingestion

›Dosing

›50 g PO or NG in adults, 1 g/kg in children

›Window within 2 hours of ingestion, consider up to 4 hours given delayed absorption and enterohepatic recirculation

›Prerequisite

›Protected airway

›Hemodialysis

›Rationale

›Dabigatran is approximately 35 percent protein bound and dialyzable

›Use case

›Idarucizumab unavailable or ongoing life-threatening bleeding with renal impairment prolonging clearance

Factor Xa inhibitor reversal

›Andexanet alfa for apixaban or rivaroxaban

›Low-dose regimen

›Bolus 400 mg IV at approximately 30 mg/min

›Infusion 4 mg/min for up to 120 minutes, total 480 mg

›High-dose regimen

›Bolus 800 mg IV at approximately 30 mg/min

›Infusion 8 mg/min for up to 120 minutes, total 960 mg

›Criteria selecting low versus high dose

›Apixaban 5 mg or less, or rivaroxaban 10 mg or less, last taken at any time, use low dose

›Apixaban more than 5 mg or unknown dose, or rivaroxaban more than 10 mg or unknown dose, taken within 8 hours or time unknown, use high dose

›Any dose of either agent taken more than 8 hours earlier, use low dose

›Adverse effects and monitoring

›Thrombotic events reported in the days following administration

›Infusion reaction monitoring

›4-factor prothrombin complex concentrate when andexanet alfa unavailable or not indicated

›Dosing

›50 units/kg IV single dose, institutional protocols vary from 25 to 50 units/kg

›Use case

›Edoxaban toxicity, where andexanet alfa labeling does not apply

›Andexanet alfa unavailable or cost-prohibitive

›Activated charcoal for very recent ingestion

›Dosing

›50 g PO or NG in adults, 1 g/kg in children, within 2 hours of ingestion

›Hemodialysis limitation

›Rationale

›Apixaban and rivaroxaban are more than 90 percent protein bound and not effectively removed by dialysis

Heparin reversal

›Protamine for unfractionated heparin

›Standard dosing

›1 mg protamine IV neutralizes approximately 100 units of unfractionated heparin given in the preceding 2 to 3 hours

›Maximum single dose 50 mg

›Time-since-dose adjustment

›Heparin given less than 30 minutes earlier, 1 mg protamine per 100 units

›Heparin given 30 to 60 minutes earlier, 0.5 to 0.75 mg protamine per 100 units

›Heparin given 60 to 120 minutes earlier, 0.375 to 0.5 mg protamine per 100 units

›Heparin given more than 120 minutes earlier, 0.25 to 0.375 mg protamine per 100 units

›Rationale is unfractionated heparin's short half-life of approximately 60 to 90 minutes

›Administration limit

›Infuse over at least 10 minutes, maximum rate 5 mg/min, to limit hypotension and anaphylactoid reaction

›Protamine for low molecular weight heparin

›Partial effect only

›Dosing 1 mg protamine per 100 anti-Xa units of enoxaparin if within 8 hours of last dose

›0.5 mg protamine per 100 anti-Xa units if 8 to 12 hours since last dose

›Not generally given beyond 12 hours since last dose

›Why it is only partial

›Neutralizes approximately 60 to 75 percent of anti-Xa activity

›Does not bind the smaller pentasaccharide fragments responsible for residual anti-Xa effect

›Neutralizes anti-IIa activity more completely than anti-Xa activity

›Protamine's own risks

›Anaphylaxis and anaphylactoid reaction

›Higher risk with fish allergy, prior protamine exposure, NPH insulin use, or vasectomy

›Hypotension

›Related to rapid infusion rate

›Mitigated by the infusion-rate limit above

Antiplatelet-associated bleeding

›Platelet transfusion

›Not routinely indicated in intracranial hemorrhage

›Trial evidence associates platelet transfusion with worse functional outcome and higher death or dependence in spontaneous intracranial hemorrhage on antiplatelet therapy

›Reserved use

›Planned neurosurgical intervention

›Severe concurrent thrombocytopenia

›Tranexamic acid

›Dosing

›1 g IV over 10 minutes, then 1 g IV over 8 hours

›Role and limits

›Antifibrinolytic mechanism, does not reverse platelet inhibition

›Evidence strongest in trauma hemorrhage and early traumatic brain injury

›Benefit in isolated spontaneous intracranial hemorrhage is not well established

›Caution or avoidance with active or high-risk arterial or venous thromboembolism given its prothrombotic mechanism

›Fibrinogen and cryoprecipitate

›Cryoprecipitate

›10 units IV targeting fibrinogen above 1.5 to 2.0 g/L

›Fibrinogen concentrate alternative

›25 to 50 mg/kg IV where available

Monitoring and troubleshooting during reversal

›Monitoring cadence

›Andexanet alfa infusion

›Vitals and neurologic checks every 15 minutes during the 120-minute infusion

›Post-reversal coagulation recheck

›INR or anti-Xa activity approximately 30 minutes after dosing, then periodically

›Massive transfusion protocol

›Ionized calcium and ECG monitoring for citrate toxicity causing hypocalcemia and QT prolongation

›Potassium monitoring for hyperkalemia from rapid transfusion of stored red cells

›Therapy not working

›Coagulation parameters not improving after appropriate reversal dosing

›Consider dosing error or inadequate product

›Consider ongoing consumption from disseminated intravascular coagulation or dilutional coagulopathy from large-volume resuscitation

›Consider unrecognized additional anticoagulant or antiplatelet agent

›Consider hepatic synthetic failure limiting response

›Bleeding continues despite normalized coagulation studies

›Reassess for a structural or surgical source requiring endoscopic, interventional, or surgical hemostasis

›Reversal corrects coagulopathy, not an anatomic bleeding source

Iatrogenic harms of routine emergency department interventions

›Intervention-by-intervention review

›Intubation

›Avoid nasotracheal route and nasogastric tube placement given epistaxis and nasopharyngeal hemorrhage risk in coagulopathy

›Prefer orotracheal route with video laryngoscopy to minimize mucosal trauma

›Sedation

›Minimize deep sedation before intracranial hemorrhage is excluded or reversal is underway because it masks the serial neurologic exam that detects hematoma expansion

›Fluid loading

›Aggressive crystalloid resuscitation causes dilutional coagulopathy and worsens ongoing hemorrhage

›Favor early blood product-based resuscitation over large-volume crystalloid pending source control

›Oxygen

›Standard supplemental oxygen is not contraindicated, avoid hyperoxia once target saturation is reached

›Vasopressors

›Central line placement for vasopressor access carries insertion-site bleeding risk in coagulopathy

›Use peripheral vasopressor administration as a temporizing measure rather than delaying resuscitation for elective central access

›Mechanical circulatory support including intra-aortic balloon pump

›Femoral arterial access carries high risk of access-site and retroperitoneal hemorrhage in coagulopathy

›Relatively contraindicated until reversal is underway, involve vascular surgery if unavoidable

›Anticoagulation

›Hold all antithrombotic and antiplatelet agents

›Favor mechanical venous thromboembolism prophylaxis with intermittent pneumatic compression over pharmacologic prophylaxis until hemostasis achieved

›Fibrinolysis

›Absolutely contraindicated with active or recent significant anticoagulant effect

›Confirm anticoagulant exposure and coagulation status before any thrombolytic administration for stroke, pulmonary embolism, or myocardial infarction

›Analgesia

›Avoid intramuscular injections given hematoma risk

›Avoid NSAIDs given additive antiplatelet effect and mucosal bleeding risk

›Avoid neuraxial procedures given epidural or spinal hematoma risk, respect guideline-based intervals from last anticoagulant dose

09Special Populations/sp26

Pregnancy

›Pregnancy considerations

›Maternal stabilization priority

›Fetal monitoring once maternal status is stable and gestation is viable

›Agent-specific notes

›Warfarin is teratogenic, low molecular weight heparin is the preferred agent in pregnancy, reversal principles for heparin still apply if bleeding occurs

›Direct oral anticoagulants are not recommended in pregnancy, exposure is uncommon but reversal agents may still be used for maternal life-threatening bleeding

›Protamine and vitamin K use

›Same dosing principles as non-pregnant adults, obstetric coordination for delivery planning if unstable

Geriatric

›Older adult considerations

›Higher baseline intracranial hemorrhage risk

›Cerebral amyloid angiopathy and prior falls increase both bleeding likelihood and severity

›Renal function decline

›Dabigatran accumulation with reduced clearance, lower threshold for reversal

›Polypharmacy

›Concurrent antiplatelet or NSAID use compounding bleeding risk

›Frailty and functional impact

›Lower threshold for admission even with modest bleeding

Pediatrics

›Pediatric considerations

›Weight-based dosing for all reversal agents

›Activated charcoal 1 g/kg

›4-factor prothrombin complex concentrate and protamine dosed per kilogram using the same per-kilogram formulas as adults

›Verify against current pediatric guideline before use

›Rarity of exposure

›Unintentional ingestion of a household member's warfarin or DOAC is the most common pediatric exposure pattern

›Poison center consultation

10Background/b38

Epidemiology

›Warfarin bleeding rates

›Major bleeding occurs in approximately 1 to 3 percent of patients per year of therapy

›Intracranial hemorrhage occurs in approximately 0.3 to 0.6 percent of patients per year of therapy

›DOAC bleeding rates

›Overall major bleeding risk generally comparable to or lower than warfarin across randomized trials

›Intracranial hemorrhage risk reduced by approximately half relative to warfarin in randomized trials

›Population drivers

›Atrial fibrillation affects approximately 1 to 2 percent of the general population and a substantially higher proportion of adults over age 80

›Anticoagulants are consistently among the leading drug classes responsible for emergency department visits for adverse drug events in adults 65 and older in national surveillance data

Pathophysiology

›Warfarin mechanism

›Vitamin K epoxide reductase inhibition

›Reduced synthesis of factors II, VII, IX, X and proteins C and S

›Direct oral anticoagulant mechanisms

›Dabigatran

›Direct thrombin inhibition

›Apixaban, rivaroxaban, edoxaban

›Direct factor Xa inhibition

›Heparin mechanisms

›Unfractionated heparin

›Antithrombin potentiation inhibiting both thrombin and factor Xa

›Low molecular weight heparin

›Shorter chain length yields predominantly anti-Xa activity with less anti-IIa activity

›Reversal agent mechanisms

›Idarucizumab

›Humanized monoclonal antibody fragment with high-affinity binding to dabigatran

›Andexanet alfa

11Patient Discharge Instructions/pdi17

copy discharge instructions

›Discharge instructions

›Medication plan

›Anticoagulant hold or resume instructions explicitly stated

›Do not restart anticoagulation unless explicitly instructed by the prescribing clinician

›Analgesic guidance

›Acetaminophen up to 1000 mg every 6 hours, maximum 3000 mg per day while on anticoagulation, avoid NSAIDs

›Follow-up plan

›Prescribing clinician or anticoagulation clinic within 24 to 72 hours

›Repeat blood count or coagulation testing as arranged

›Return to emergency care immediately

›New or worsening headache

›Blood in stool or black tarry stool

›Vomiting blood

›Unusual bruising or swelling

›Fainting or near-fainting

›New weakness, numbness, or confusion

›Bleeding that does not stop with 10 minutes of direct pressure

12References/r14

Clinical guidelines and consensus

›Society guidelines

›American Heart Association and American Stroke Association guideline for management of spontaneous intracerebral hemorrhage

›American Society of Hematology 2020 guidelines for management of venous thromboembolism, anticoagulant reversal section

›American College of Cardiology expert consensus decision pathway on periprocedural management of anticoagulation

›Product labeling

›Idarucizumab prescribing information

›Andexanet alfa prescribing information

›4-factor prothrombin complex concentrate prescribing information

Evidence-based sources

›Landmark trials

›RE-VERSE AD trial of idarucizumab for dabigatran reversal

›ANNEXA-4 trial of andexanet alfa for factor Xa inhibitor reversal

›PATCH trial of platelet transfusion in antiplatelet-associated intracranial hemorrhage

›Definitional sources

›International Society on Thrombosis and Haemostasis major bleeding definition

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed September 13, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.